The Operating Grant is a two-year grant designed to provide funding to research that may ultimately lead to a significant change in the understanding, diagnosis, or treatment of blood cancer.
We are pleased to partner with the Cancer Research Society (CRS) to co-fund 15 Operating Grants this funding cycle. The CRS is a national not-for-profit organization whose sole mission is to fund research on all types of cancer, thereby contributing to the advancement of science aimed at preventing, detecting, and treating the disease.
New this year, the LLSC is pleased to announce a research funding partnership with Waldenstrom’s Macroglobulemia Foundation of Canada to fund 1 grant in this competition. The Waldenstrom’s Macroglobulinemia Foundation of Canada (WMFC) supports Canadians with WM, and their families, by offering a range of services that can enhance quality of life for those with WM and funding research to ultimately discover a cure. WM applications should address signaling, immunology/immunotherapy, tumor microenvironment, “Omics”, or IgM Monoclonal Gammopathy of Undetermined Significance (MGUS).
How to apply
The application process will occur in two phases.
Phase Ⅰ - Submission and consideration of a Letter of Intent (LOI).
Phase ⅠⅠ - Invitation to submit a Full Application.
Funds for competitive applications will be awarded on the basis of scientific merit, using a priority rating system.
Key dates for 2022-2023
- Call for Proposals - September 12, 2022
- Letter of Intent (LOI) due - October 28, 2022, 4:00pm (ET)
- Notification of Full Application Invite - November, 2022
- Full application deadline - February 3, 2023, 4:00pm (ET)
- Review Panel Meeting - April, 2023
- Notification of Awards - May, 2023
- Award Start Date - July, 2023
Read the guidelines
Applicants must carefully read the program guidelines before beginning their applications as application details have changed in 2022.
Submitting a letter of intent
Submitting a Letter of Intent is mandatory for all applicants.